Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: A randomised trial

Lancet

Volumn 354, Issue 9182, 1999, Pages 891-895

  Dunne, Michael W ^a   Bozzette, Samuel ^b,c   McCutchan, J Allen ^b   Dubé, Michael P ^d   Sattler, Fred R ^d   Forthal, Donald ^e   Kemper, Carol A ^f   Havlir, Diane ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; RIFABUTIN; SULFAMETHOXAZOLE; SULFONAMIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0033546957     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10328-8     Document Type: Article

References (31)

1. Moore R.D., Chaisson R.E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 124:1996;633-642.
2. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 1995, Vol 7 No 2. Atlanta: C.D.C., 1995: 1-21.
3. 3. J Infect Dis. 170:1994;1284-1287.
4. Fischl M.A., Dickinson G.M., La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 259:1988;1185-1189.
5. El-Sadr W.M., Murphy R.L., Yurik T.M.et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides or both. N Engl J Med. 339:1998;1889-1895.
6. Kaplan J.E., Masur H., Holmes K.K.et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis. 21(suppl 1):1995;S12-31.
7. Ioannidis J.P.A., Cappelleri J.C., Skolnik P.R., Lau J., Sacks H.S. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 156:1996;177-188.
8. Girard P.M., Landman R., Gaudebout C.et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med. 328:1993;1514-1520.
9. Antinori A., Murri R., Ammassari A.et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS. 9:1995;1343-1350.
10. Nielsen T.L., Jensen B.N., Nelsing S., Mathiesen L.R., Skinhøj P., Nielsen J.O. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Scand J Infect Dis. 27:1995;217-220.
11. Podzamczer D., Salazar A., Jiminez J.et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 122:1995;755-761.
12. Bozzette S.A., Finkelstein D.M., Spector S.A.et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med. 332:1995;693-699.
13. Saah A.J., Hoover D.R., Peng Y.et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA. 273:1995;1197-1202.
14. Waverling G.J., Mocroft A., Ledergerber B.et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 353:1999;1293-1298.
15. Smith J.W., Bartlett M.S., Queener S.F. Anti-pneumocystis activity of azithromycin in a culture model. 6th International Symposium on Infections in the Immunocompromised Host, Peebles, U.K., June, 1990 (abstr).
16. Hughes W.T. Macrolide-antifol synergism and anti-Pneumocystis carinii therapeutics. J Protozool. 38:1991;160S.
17. Havlir D.V., Dubé M.P., Sattler F.R.et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 335:1996;392-398.
18. Masur H. Empiric outpatient management of HIV-related pneumonia: economical or unwise? Ann Intern Med. 124:1996;451-453.
19. Araujo F.G., Lin T., Remington J.S. Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice. Eur J Clin Microbiol Infect Dis. 11:1992;71-73.
20. Alder J., Mitten M., Shipkowitz N.et al. Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole. J Antimicrob Chemother. 33:1994;253-263.
21. Hughes W.T., Killmar J.T. Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. J Acquir Immune Defic Syndr. 4:1991;532-537.
22. Young L.S., Wiviott L., Wu M., Kolonoski P., Bolan R., Inderlied C.B. Azithromycin for treatment of Mycobacterium avium-intracellulare infection in patients with AIDS. Lancet. 338:1991;1107-1109.
23. Cynamon M.H., Klemens S.P. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother. 36:1992;1611-1613.
24. Oldfield E.C. Jr., Fessel W.J., Dunne M.W.et al. Once weekly azithromycin therapy for the prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 26:1998;611-619.
25. Carpenter C.C.J., Fischl M.A., Hammer S.M.et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 276:1996;146-154.
26. Harris S., Hilligoss D.M., Colangelo P.M., Eller M., Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther. 58:1995;310-315.
27. Honig P.K., Wortham D.C., Zamani K., Cantilena L.R. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 7:1994;148-156.
28. Foulds G., Willavize S.A., Luke D.R., Stretcher B.N., Trapnell C.B. Effect of concomitant azithromycin (AZM) on the pharmacokinetics of zidovudine (ZDV). Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, January, 1996 (abstr).
29. Flaherty J., Halle L.G., Foulds G., et al. Effect of azithromycin (AZM) on the pharmacokinetics of didanosine. Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, January, 1996 (abstr).
30. Chave J.P., Munafo A., Chatton J.Y., Dayer P., Glauser M., Biollaz J. Once-a-week azithromycin in AIDS patients: tolerability, kinetics and effects on zidovudine disposition. Antimicrob Agents Chemother. 36:1992;1013-1018.
31. Apseloff G., Foulds G., LaBoy-Goral L., Willavize S., Vincent J. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol. 38:1998;830-835.